FDA actions in brief

News
Article

Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.

Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.

FDA approved 2 higher dose formulations of valsartan/hydrochlorothiazide (Diovan HCT, Novartis) for the treatment of hypertension. The combination tablets will now be available in 320/12.5 mg and 320/25 mg doses.

FDA approved infliximab (Remicade, Centocor) to treat children aged 6 to 17 years with active Crohn's disease.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.